Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar
The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial development partners for its later stage, highly novel asset for treatment of serious cardiopulmonary disease. Respira’s initial pipeline is targeting two indications with large unmet medical needs, with market potentials likely in excess of $1Bn each. Respira is a privately funded US-based company focused on treatment of cardiopulmonary disease